These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 31682979)

  • 21. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
    Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
    Vigouroux S; Michallet M; Porcher R; Attal M; Ades L; Bernard M; Blaise D; Tabrizi R; Garban F; Cassuto JP; Chevalier P; Facon T; Ifrah N; Renaud M; Tilly H; Vernant JP; Kuentz M; Bourhis JH; Bordigoni P; Deconinck E; Lioure B; Socié G; Milpied N;
    Haematologica; 2007 May; 92(5):627-34. PubMed ID: 17488686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.
    Chamoun K; Milton DR; Ledesma C; Young KH; Jabbour EJ; Alatrash G; Anderlini P; Bashir Q; Ciurea SO; Marin D; Molldrem JJ; Olson AL; Oran B; Popat UR; Rondon G; Champlin RE; Gulbis AM; Khouri IF
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1347-1354. PubMed ID: 30826465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma.
    Chen YB; Li S; Fisher DC; Driscoll J; Del Rio C; Abramson J; Armand P; Barnes J; Brown J; Cutler C; El-Jawahri A; Ho VT; Hochberg E; McAfee S; Takvorian R; Spitzer TR; Antin JH; Soiffer R; Jacobsen E
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1583-8. PubMed ID: 26009261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Myeloablative versus Reduced-Intensity Conditioning Regimens in Allogeneic Stem Cell Transplantation Recipients with Acute Myelogenous Leukemia with Measurable Residual Disease-Negative Disease at the Time of Transplantation: A Retrospective Cohort Study.
    Yu J; Du Y; Ahmad S; Patel RD; Varela JC; Chang CC; Mori S
    Transplant Cell Ther; 2021 Aug; 27(8):663.e1-663.e6. PubMed ID: 33951497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant.
    Savani M; Ahn KW; Chen Y; Ahmed S; Cashen AF; Shadman M; Modi D; Khimani F; Cutler CS; Zain J; Brammer JE; Rezvani AR; Fenske TS; Sauter CS; Kharfan-Dabaja MA; Herrera AF; Hamadani M
    Br J Haematol; 2022 Apr; 197(2):212-222. PubMed ID: 35106754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL.
    Dreger P; Sureda A; Ahn KW; Eapen M; Litovich C; Finel H; Boumendil A; Gopal A; Herrera AF; Schmid C; Diez-Martin JL; Fuchs E; Bolaños-Meade J; Gooptu M; Al Malki MM; Castagna L; Ciurea SO; Dominietto A; Blaise D; Ciceri F; Tischer J; Corradini P; Montoto S; Robinson S; Gülbas Z; Hamadani M
    Blood Adv; 2019 Feb; 3(3):360-369. PubMed ID: 30723110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial.
    Vose JM; Carter S; Burns LJ; Ayala E; Press OW; Moskowitz CH; Stadtmauer EA; Mineshi S; Ambinder R; Fenske T; Horowitz M; Fisher R; Tomblyn M
    J Clin Oncol; 2013 May; 31(13):1662-8. PubMed ID: 23478060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Genadieva-Stavrik S; Boumendil A; Dreger P; Peggs K; Briones J; Corradini P; Bacigalupo A; Socié G; Bonifazi F; Finel H; Velardi A; Potter M; Bruno B; Castagna L; Malladi R; Russell N; Sureda A
    Ann Oncol; 2016 Dec; 27(12):2251-2257. PubMed ID: 28007754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Updated Results of Rituximab Pre- and Post-BEAM with or without
    Chahoud J; Sui D; Erwin WD; Gulbis AM; Korbling M; Zhang M; Ahmed S; Alatrash G; Anderlini P; Ciurea SO; Oran B; Fayad LE; Bassett RL; Jabbour EJ; Medeiros LJ; Macapinlac HA; Young KH; Khouri IF
    Clin Cancer Res; 2018 May; 24(10):2304-2311. PubMed ID: 29476021
    [No Abstract]   [Full Text] [Related]  

  • 32. Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis.
    Braitsch K; Schwarz A; Koch K; Hubbuch M; Menzel H; Keller U; Götze KS; Bassermann F; Herhaus P; Verbeek M
    Ann Hematol; 2022 Jun; 101(6):1311-1319. PubMed ID: 35364726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.
    Evens AM; Vanderplas A; LaCasce AS; Crosby AL; Nademanee AP; Kaminski MS; Abel GA; Millenson M; Czuczman MS; Rodriguez MA; Niland J; Zelenetz AD; Gordon LI; Friedberg JW
    Cancer; 2013 Oct; 119(20):3662-71. PubMed ID: 23921646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Rodríguez-Arbolí E; Labopin M; Tischer J; Brecht A; Ganser A; Finke J; Blau IW; Kröger N; Kalhs P; Forcade E; Bunjes D; Spyridonidis A; Savani B; Nagler A; Mohty M
    Biol Blood Marrow Transplant; 2020 Nov; 26(11):2165-2173. PubMed ID: 32717436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study.
    Bento L; Gutiérrez A; Novelli S; Montoro J; Piñana JL; López-Corral L; Cabrero M; Martín-Sancho A; Gutiérrez-García G; Ortiz-Moscovich M; Bastos-Oreiro M; Dorado N; Pérez A; Hernani R; Ferrà C; Parody R; García-Cadenas I; Herrera P; Rodríguez G; Rodríguez N; Martín C; Yáñez L; Zanabili J; Varela MR; López-Godino O; Heras I; Español I; Martínez C; Pérez-Simón JA; Solano C; Sureda A; Sierra J; Sampol A; Caballero D;
    Bone Marrow Transplant; 2021 Aug; 56(8):1919-1928. PubMed ID: 33767400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
    Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
    Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
    Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party.
    Robinson SP; Boumendil A; Finel H; Blaise D; Poiré X; Nicolas-Virelizier E; Or R; Malladi R; Corby A; Fornecker L; Caballero D; Pohlreich D; Nagler A; Thieblemont C; Finke J; Bachy E; Vincent L; Schroyens W; Schouten H; Dreger P
    Bone Marrow Transplant; 2016 Mar; 51(3):365-71. PubMed ID: 26618550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
    McLornan D; Szydlo R; Koster L; Chalandon Y; Robin M; Wolschke C; Beelen D; Socié G; Bornhäuser M; Angelucci E; Niederwieser D; Gerbitz A; Finke J; Vitek A; Itälä-Remes M; Radujkovic A; Kanz L; Potter V; Chevallier P; Stelljes M; Petersen E; Robinson S; Poiré X; Klyuchnikov E; Hernández-Boluda JC; Czerw T; Hayden P; Kröger N; Yakoub-Agha I
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2167-2171. PubMed ID: 31284069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
    Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
    Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.